Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany

Thresholds for the cost–effectiveness of interventions: alternative approaches

(2015) Elliot Marseille et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review

(2014) T Brown et al.   HEALTH TECHNOLOGY ASSESSMENT

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Afatinib in the treatment of EGFR mutation-positive NSCLC – A network meta-analysis

(2014) Sanjay Popat et al.   LUNG CANCER

Is Individualized Medicine More Cost-Effective? A Systematic Review

(2014) Maximilian H. M. Hatz et al.   PHARMACOECONOMICS

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

(2014) Wenhua Liang et al.   PLoS One

A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)

(2014) Ansgar Lange et al.   BMC Pulmonary Medicine

Population-Based Risk for Complications After Transthoracic Needle Lung Biopsy of a Pulmonary Nodule: An Analysis of Discharge Records

(2013) Renda Soylemez Wiener et al.   ANNALS OF INTERNAL MEDICINE

Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis

(2013) Jun Zhu et al.   BMC CANCER

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice

(2013) S Gahr et al.   BRITISH JOURNAL OF CANCER

The prevalence of weight loss during (chemo)radiotherapy treatment for lung cancer and associated patient- and treatment-related factors

(2013) Nicole Kiss et al.   CLINICAL NUTRITION

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies

(2013) Xiaoqing Liu et al.   JOURNAL OF CLINICAL PATHOLOGY

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

(2013) Neal I. Lindeman et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Economic burden of cancer across the European Union: a population-based cost analysis

(2013) Ramon Luengo-Fernandez et al.   LANCET ONCOLOGY

Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany

(2013) Shrividya Iyer et al.   LUNG CANCER

Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data

(2013) Nicholas R. Latimer   MEDICAL DECISION MAKING

A Systematic Review of Utility Values for Chemotherapy-Related Adverse Events

(2013) Fatiha H. Shabaruddin et al.   PHARMACOECONOMICS

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

(2012) Ji-Youn Han et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME)

(2012) Philipp A. Schnabel et al.   LUNG CANCER

Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies

(2012) Arne Warth et al.   VIRCHOWS ARCHIV

Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung

(2012) Elizabeth A. Handorf et al.   Journal of Oncology Practice

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

(2011) Gilberto de Lima Lopes et al.   CANCER

9144 POSTER EGFR Mutation Testing and First Line Treatment of Patients With Advanced NSCLC and Positive EGFR Mutation Status – Results From a German Registry

(2011) W. Eberhardt et al.   EUROPEAN JOURNAL OF CANCER

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3

(2011) I. Borget et al.   EUROPEAN RESPIRATORY JOURNAL

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

(2010) Yumi Asukai et al.   BMC CANCER

The efficiency frontier approach to economic evaluation of health-care interventions

(2010) J. Jaime Caro et al.   HEALTH ECONOMICS

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health state utilities for non small cell lung cancer

(2008) Beenish Nafees et al.   Health and Quality of Life Outcomes

The NICE Cost-Effectiveness Threshold

(2008) Christopher McCabe et al.   PHARMACOECONOMICS

Health State Utility Scores for Cancer-Related Anemia through Societal and Patient Valuations

(2008) Andrew Lloyd et al.   VALUE IN HEALTH

The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer

(2008) Josh J. Carlson et al.   VALUE IN HEALTH